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Abstract In the last decade, there has been important progress in understanding the origins and 
evolution of receptors for adrenal steroids (aldosterone, cortisol) and sex steroids (estradiol, 
progesterone, testosterone) due to the sequencing of genomes from animals that are at key sites 
in vertebrate evolution.  Although the estrogen receptor [ER] appears to be the ancestral 
vertebrate steroid receptor and estradiol [E2] is the physiological ligand for vertebrate ERs, the 
identity of the ancestral ligand(s) for the ER remains unknown.  Here, using an analysis of 
crystal structures of human ER  with E2 and other chemicals and 3D models of human ER  
with 27-hydroxycholesterol and 5-androsten-3 ,17 -diol, we propose that one or more 5 
steroids were the ancestral ligands for the ER, with E2 evolving later as the canonical estrogen.  
The evidence that chemicals with a -hydroxy at C3 in a saturated A ring can act as estrogens 
and the conformational flexibility of the vertebrate ER can explain the diversity of synthetic 
chemicals that disrupt estrogen responses by binding to vertebrate ERs. 
 
1. Introduction 
The adrenal steroids, aldosterone and cortisol, and sex steroids, estradiol (E2), 
progesterone and testosterone, regulate a wide range of physiological processes including 
reproduction, development and homeostasis [Figure 1].  The physiological actions of these 
vertebrate steroids are mediated by nuclear receptors, a large and diverse group of transcription 
factors that arose in multicellular animals [1-4].  Nuclear receptors with transcriptional 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.5
77
7.
1 
: P
os
te
d 
13
 M
ar
 2
01
1
  
2 
responses to adrenal and sex steroids appear to have evolved in deuterostomes [5-7]; the estrogen 
receptor [ER] is the ancestral vertebrate steroid receptor [6-11]. 
 
Figure 1. Structures of adrenal and sex steroids. The A ring of Estradiol has a C3 phenolic 
group.  The A ring in the other steroids has a C3-ketone. 
 
In addition to an ER, the chordate amphioxus contains a steroid receptor [SR], which 
diversified in vertebrates into the androgen receptor [AR], glucocorticoid receptor [GR], 
mineralocorticoid receptor [MR] and progesterone receptor [PR] [8-9, 12-14].  Although 
mollusks and annelids contain receptors with sequence similarity to the human ER [15-17], there 
is disagreement as to whether these protostome receptors diverged from a common ancestor of 
chordate ER [17], or if the similarity between protostome proteins and the chordate ER is an 
example of convergent evolution [18-20].  The pros and cons of this controversy are discussed 
in [17-20] and are not the focus of this paper. 
 
1.1 What was the ancestral ligand for the ER? 
Here, we investigate another unresolved question about the ER: the identity of the 
ligand(s) for the ancestral ER [3, 7, 18, 21].  Phylogenetic analyses of lamprey and other 
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vertebrate steroid receptors established that the ER was the ancestral steroid receptor [7].  
Duplication of this ER followed by sequence divergence led to the ancestral 3-keto-steroid 
receptor, which through further duplications and divergence led to the AR, GR, MR and PR [1, 
6-7].  A problem with having the ER as the ancestral receptor is that estradiol [E2], the 
physiological ligand for vertebrate ERs, is at the end of the pathway for the synthesis of steroids 
from cholesterol [7, 22] [Figure 2]. 
 
 
Figure 2. Enzymes involved in the synthesis of vertebrate steroids from cholesterol 
CYP450s, 3 /
5-4
-HSD and 17 -HSD-type 2 catalyze the formation of vertebrate steroids from 
cholesterol [18, 51-52]. 
 
E2 is synthesized from either testosterone, or from estrone [E1], which is synthesized 
from androstenedione.  Thus, the AR would have been expected to have evolved before the ER.  
Moreover, 3 /
5-4
-hydroxysteroid dehydrogenase [3 /
5-4
-HSD], which catalyzes the synthesis 
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of androstenedione from DHEA, also catalyzes the synthesis of progesterone from pregnenolone.  
Thus, the PR also would have been expected to have evolved before the ER.  To solve this 
conundrum, Thornton [7] proposed the ligand exploitation model, in which vertebrate steroids 
that are upstream of E2, were present before their receptors evolved.  In this model, 
progesterone and testosterone were present before the evolution of the PR and AR respectively.  
Progesterone and testosterone assumed novel signaling functions after the evolution of the PR 
and AR. 
In an alternative model, 5-androsten-3 ,17 -diol [
5
-androstenediol], which is upstream 
of E2, has been proposed as a ligand for the ancestral ER [22-23] [Figure 3]. 
 
Figure 3. Synthesis of 
5
-androstenediol and 3 -Adiol.  Synthesis of 
5
-androstenediol and 
3 -Adiol does not require aromatase [CYP19].  Moreover, synthesis of 
5
-androstenediol does 
not require 3 /
5-4
-HSD.  
5
-androstenediol and 3 -Adiol have high affinity for the ER [30]. 
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Here, we provide support for this latter hypothesis, using data from crystal structures of 
human ER  with E2 and other steroids and 3D models of human ER  with 5 steroids.  As 
discussed later, our analysis of crystal structures of human ER with novel steroids and 3D 
models of human ER with oxy-sterols also has implications for the binding to the ER of diverse 
synthetic chemicals, which can disrupt estrogen physiology in vertebrates [24-28]. 
 
2. Methods 
The Insight II software and the Biopolymer and Discover 3 options were used to 
construct 3D models of human ER  [PDB:1G50] with 
5
-androstenediol, 3 -Adiol, 27-OH-C 
and 24-OH-C, as described previously for constructing 3D models of 15 -hydroxy-estradiol 
complexed with human ER  and lamprey ER [29].  The crystal structure of human ER  with 
E2 was opened with Insight II.  Then the Biopolymer option in Insight II was used to modify 
E2 to 
5
-androstenediol, 3 -Adiol, 24-OH-C and 27-OH-C.  Then the 3D model of ER  with 
each of these ligands was refined through energy minimization with Discover 3 for 10,000 
iterations using the CVFF force field, with a distant dependent dielectric constant of 2.  The 
final 3D models of ER  with 
5
-androstenediol, 3 -Adiol, 24-OH-C and 27-OH-C are shown in 
Figures 6A, 6B, 8 and 9, respectively. 
The crystal structure of human ER  with trifluoromethyl-phenylvinyl-E2 [PDB: 2P15] 
was downloaded for analysis with Insight II. 
 
3. Structural Determinants for Binding of Estradiol to the ER 
Estrogens such as E2 and diethylstilbestrol [DES], which activate ER  and ER  [30], 
contain a C3-phenolic group [Figure 4], which also is required for high affinity binding to the ER 
by anti-estrogens, such as 4-hydroxy-tamoxifen, because tamoxifen is inactive [30] [Figure 4].  
The crystal structures of human ER  with E2 [31-32], DES [33] and 4-hydroxy-tamoxifen [33] 
provide a structural explanation for importance of the C3-phenolic group on E2 and other 
estrogens. 
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Figure 4. Structures of estrogens and an anti-estrogen  E2 and DES, two estrogens, and 
4-hydroxy-tamoxifen, an anti-estrogen have a phenolic A ring, which is important in their high 
affinity for the human ER. 
 
As shown in Figure 5, the C3 phenolic group has a hydrogen bond with the -carboxylate 
of Glu-353 in human ER .   
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Figure 5. Key amino acids in human ER  that bind E2.  The crystal structure of human 
ER  with E2 reveals that the A ring of E2 has hydrogen bond with -carboxylate of Glu-353 [4, 
31-32].  This interaction is characteristic of the ER  and ER .  In receptors for 3-keto-steroids, 
Glu is replaced by Gln, in which the amido NH2 group donates a hydrogen bond to the 3-keto 
group. 
 
The specificity of this interaction for the ER is seen in the replacement of Glu-353 by a 
corresponding Gln in the PR [32, 34] and AR, MR and GR [4], which are activated by steroids 
with 3-keto-groups [Figure 1].  The amido NH2 group on this Gln donates a hydrogen bond to 
the 3-keto-group on progesterone, testosterone, cortisol and aldosterone [4]. 
3.1 Human ERa binds 
5
-androstenediol and 5 -androstane-3 ,17 -diol with high affinity 
The evidence that the major physiological estrogens, E2 and E1, and anti-estrogens, such 
as 4-hydroxy-tamoxifen and raloxifene [31], have an aromatic A ring supports the notion that 
aromatase [CYP19] was necessary for the evolution of the steroid that activated the ancestral ER 
[17].  However, steroids that lack an aromatic A ring and contain a 3 -hydroxyl group, such as 
5
-androstenediol and 5 -androstane-3 ,17 -diol [3 -Adiol] also have high affinity for the 
mammalian ER [30] and could have served as ligands for the ancestral ER [22-23].  Indeed, 
3 -Adiol is an active estrogen in the prostate [35], as well as in the brain, under conditions in 
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which E2 is not present [36].  As shown in Figure 3, synthesis of 
5
-androstenediol and 
3 -Adiol does not require aromatase [CYP19].  Thus, either steroid could have been an active 
estrogen before the evolution of CYP19.  Moreover, 
5
-androstenediol could have been an 
active estrogen before the evolution of 3 /
5-4
-HSD [22-23]. 
Our 3D models of human ER  with 
5
-androstenediol and 3 -Adiol reveal that 
stabilizing contacts are retained between the 3 -hydroxyl and Glu-353 and Arg-394 and between 
the 17 -hydroxyl and His-524 [Figure 6], which is consistent with the evidence that both steroids 
have nM affinity for ER  and ER  [30] . This expands the ligands that can bind to the ER to 
include steroids with a 3 -hydroxyl on a saturated A ring. 
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Figure 6. Interaction of human ER  with 
5
-androstenediol and 3 -Adiol 
A. 3D model of human ER  with 
5
-androstenediol  
B. 3D model of human ER  with 3 -Adiol. 
In both 3D models, the 3 -hydroxyl group on 
5
-androstenediol and 3 -Adiol has favorable 
contacts with Glu-353 and Arg-394.  The 17 -hydroxyl on 
5
-androstenediol and 3 -Adiol has 
a favorable contact with His-524. 
 
3.2 Human ER  can accommodate steroids with large substituents in the D ring 
E2 has the smallest van der Waals volume of the vertebrate steroids [37] and the ER has 
the smallest ligand-binding cavity of vertebrate steroid receptors [38].  Crystal structures of the 
ER place the estrogen-binding site in a hydrophobic cavity, with select polar residues stabilizing 
the A and D rings.  These polar residues are Glu-353 and Arg-394, which stabilize the A ring, 
and His-524, which caps the D ring with a hydrogen bond to the 17 -hydroxyl that is 
characteristic of the ER [Figure 5].  Conversion of the 17 -hydroxyl to a ketone, as found in E1, 
reduces the affinity for the ER [30].  The lack of a C17 side chain in E2, in contrast to 
aldosterone, cortisol and progesterone [Figure 1], and the compact ligand-binding cavity in the 
ER indicated that compact ligands bind to the ER. 
However, in the last decade it has become clear that there is substantial conformational 
flexibility in the ER, which allows high affinity binding of E2 analogs with large substituents at 
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C17 to E2.  An important example is trifluoromethyl-phenylvinyl-E2 (TFMPV-E2), which has 
a bulky 17 -substituent and a Kd of about 50 pM for human ER  [39].  TFMPV-E2 is an 
agonist for human ER .  To understand the molecular interaction of TFMPV-E2 with human 
ER , they were cocrystallized (PDB 2P15) by Nettles et al.  Analysis of this crystal structure 
[Figure 7] revealed that despite the bulky substituent at C17 on TFMPV-E2, it has favorable 
contacts with key residues in the ligand-binding pocket [39]. 
 
 
Figure 7. Human ER  complexed with TFMPV-E2  The crystal structure of human ER  
with TFMPV-E2 [PDB: 2P15] [39] was downloaded for analysis with Insight II.  Despite the 
large 17 -substituent, TFMPV-E2 has favorable contacts with His-524 and no steric clashes with 
ER .  In fact, TFMPV-E2 is a potent estrogen with a Kd of about 50 pM for human ER  [39]. 
 
4. Was the ancestral estrogen a cholesterol analog? 
The finding that transcription by the ER can be activated by an estradiol analog with a 
bulky substituent at C17 indicates that a steroid with a large substituent at C17 could have been 
the ligand that activated the ancestral ER, which would be expected to have a different sequence 
from mammalian ERs, as well as a different cellular milleu.  Recently, Umetani et al [40] 
reported that several hydroxylated cholesterols including 27-hydroxycholesterol [27-OH-C], 
22R-OH-C, 24S-OH-C and 25-OH-C bound human ER  and human ER .  27-OH-C was the 
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most potent, and in some mammalian cells 27-OH-C functions as a partial agonist for human 
ER  and ER  [40-43].  The Kd of 27-OH-C for ER  and ER  is about 1.3 M and 0.4 M, 
respectively [40-42], which is over 10
3
 times higher than the Kd of E2 for human ER  and ER  
[30, 40].  Nevertheless, a Kd of 1 M is physiologically relevant because the circulating 
concentration of 27-OH-C is from 0.15 to 0.73 M, [40-42]. 
To understand the molecular interaction of 27-OH-C with human ER , we constructed a 
3D model of human ER  with 27-OH-C [Figure 8].  The 3D model reveals that binding of the 
A ring to Glu-353 and Arg-394 on human ER  is favorable, but His-524 does not have a 
stabilizing hydrogen bond with 27-OH-C [Figure 8], which may explain the low affinity of 
human ER for 27-OH-C. 
 
 
Figure 8. 3D model of human ER  with 27-hydroxycholesterol  The 3D model of human 
ER  with 27-OH-C shows that Glu-353 and Arg-394 are 2.6A and 3.1A, respectively, from the 
C3-hydroxyl.  His-524 on ER  does not contact the 27-hydroxyl, which may explain the 
substantially the lower affinity of 27-OH-C for ER  and ER  [40-42]. 
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The 3D model in Figure 8 indicates that a C24-hydroxyl on cholesterol could have a 
stabilizing contact with His-524.  In Figure 9, we show a 3D model of human ER  complexed 
with 24-OH-C, which shows that the C24 hydroxyl is 3.3A from His-524.  Bioassays are 
needed to determine if 24-OH-C has estrogen agonist or antagonist activity. 
 
 
 
Figure 9. 3D model of human ER  with 24-hydroxycholesterol  The 3D model of human 
ER  with 24-OH-C shows that Glu-353 and Arg-394 are 2.6A and 3.0A, respectively, from the 
C3-hydroxyl.  His-524 on ER  is 3.3A from the 24-hydroxyl.  There are no steric clashes 
between 24-OH-C and amino acids in the 3D model of human ER . 
 
The partial agonist activity of 27-OH-C for human ER  is relevant for the identity of 
ligand that activated transcription by ancestral ER.  The 
5
-ligand that regulated estrogen 
physiology through binding to the ancestral ER may have been 27-OH-C, 24-OH-C or another 
hydroxy-cholesterol derivative.  Regarding the ancestral ligand, an important consideration is 
that the ancestral ER would be expected to have a different sequence from mammalian ERs, and, 
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thus, may have a higher affinity for a cholesterol analog or another ligand than has a mammalian 
ER.  Also, the cellular milleu for the ancestral ER is likely to differ from that in mammalian 
cells.  For example, the ancestral ER-ligand complex may have had increased transcriptional 
activity due to binding to ancestral co-activators, which differ from their mammalian orthologs.  
If a cholesterol analog is the ancestral estrogen then it would support the model of Markov and 
Laudet that the estrogen response evolved before the cholesterol side-chain cleavage enzyme 
CYP11A [20].  It also means that a cholesterol analog preceded 
5
-androstenediol or another 
5
-derivative of DHEA as the physiological estrogen for the ancestral ER. 
The different physiological concentrations of steroids and cholesterol may have been 
important in the evolution of steroids as ligands for vertebrate nuclear receptors.  In contrast to 
the high concentration of cholesterol in blood, vertebrate steroid concentrations are at nM or 
lower levels, consistent with the nM affinities of vertebrate steroids for their cognate receptors.  
Thus, the evolution of CYP11A and CYP17 would provide a transition to C21 or C19 ligands 
that would function at nM concentrations to regulate transcription by the ER and other vertebrate 
steroid receptors. 
 
5. Implications for disruption of estrogen physiology by xenobiotics 
An unexpected outcome in preparing this commentary was the discovery that the ER can 
accommodate ligands such as TFMPV-E2 and 27-OH-C, which have larger substituents at C17 
than does E2.  The conformational elasticity in the ligand-binding site of the ER and the 
evidence that the ER can be activated by ligands with a 3 -hydroxyl instead of a C3-phenolic 
group substantially expands the suite of chemicals that need to be considered as possible 
disruptors of normal functioning of the ER in vertebrate physiology.  Indeed, although there is 
evidence that the ER binds environmental chemicals with diverse structures [Figure 10] [25, 
27-28], synthetic chemicals and phyotchemicals that lack key features of E2 should not be 
assumed to be inert towards the ER as either agonists or antagonists. 
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Figure 10. Chemicals with diverse structures bind to the ER.  Bisphenol A and genistein 
contain hydroxyls that can mimic some of the properties of the C3 and C17 hydorxyls on 
estradiol.  Coumestrol has only one hydroxyl.  Methoxychlor, o,p’-DDT, 
2’,3’,4’,5’-Tetrachloro-4-biphenyl and 2,3,7,8-Tetrachloro-dibenzodioxin (2,3,7,8-TCDD) lack 
hydroxyl substituents. 
 
Before one assumes that these chemicals do not disrupt estrogen physiology, they should 
to be screened in silico for binding to vertebrate ER  and ER  using various docking algorithms 
[44-45].  Chemicals with high docking scores can be tested for agonist or antagonist activity 
with high throughput screening of cells containing an ER and a reporter gene. 
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Interestingly, conformational flexibility in the ligand-binding pocket has been found in 
other nuclear receptors.  The ligand binding pocket on the GR can accommodate steroid 
analogs that are substantially larger than cortisol.  In particular, deacylcortivazol, which has a 
large substituent at the A ring and thus lacks a C3 ketone, has a 10-fold higher affinity for the 
GR than does dexamethasone [46].  The crystal structure of the GR-deacylcortivazol complex 
[PDB:3BQD] shows that the ligand binding pocket doubles in size.  Crystal structures of LXR 
[PDB:1PQ6, 1PQ9, 1PQC] [47], the ecdysone receptor [PDB 1R20, 1R1K] [48] and thyroid 
hormone receptor [PDB:1X7X, 1Y0X] [49-50] indicate that these receptors have a flexible 
ligand-binding pocket.  Thus, these receptors also may bind chemicals that are larger than their 
cognate ligands, with important implications for disruption of their physiological activity. 
Lastly, conformational flexibility of the ligand-binding pocket in the ER and other 
nuclear receptors may have been important in the evolution of their response to oxysterols and 
vertebrate hormones from ancestral signals [3, 18, 20]. 
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